An international, open-label, sequential-cohort, phase 2 study (CONTROL) in HER2 + breast cancer patients receiving extended adjuvant neratinib therapy [59–61] is currently investigating the effects of several prophylactic strategies in reducing neratinib-associated diarrhea. Here, ERBB2 is linked to breast carcinoma.